key: cord-0733589-0vbk9xkc
authors: Goldman, Jason D
title: Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic
date: 2020-11-07
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1707
sha: 93fd866c798a6a71316d51fe7d6281d69e6ac6fc
doc_id: 733589
cord_uid: 0vbk9xkc

nan

A c c e p t e d M a n u s c r i p t

Since the first days of the Covid-19 pandemic, healthcare workers were at high risk for acquiring SARS-CoV-2 infection, and at risk for death. Dr. Li Wenliang, a physician in Wuhan, China, sounded the alarm on social media about an unexplained viral pneumonia and later succumbed to the infection. 1 As the pandemic quickly spread around the world, a lack of any treatments or preventatives known to be effective, coupled with critical gaps in personal protective equipment (PPE) in the United States and elsewhere left front-line healthcare workers scared and vulnerable. In vitro studies suggested that aminoquinolines, such as hydroxychloroquine (HCQ), were effective in inhibiting SARS-CoV-2 infection in a cell culture model, 2, 3 and modeling studies predicted dosing in silico. 4 The putative mechanism of action was unknown, but was speculated to be pleotropic. 5 In the setting of this uncertainty and risk, Dr. Rajasingham et al. rapidly designed and implemented a double-blind, placebo-controlled RCT to evaluate the use of hydroxychloroquine (HCQ) to prevent Covid-19, as pre-exposure prophylaxis (PrEP), i.e. COVID PrEP trial. 6 They enrolled healthcare workers in front-line positions at high risk for acquiring SARS-CoV-2 (79% performed aerosol generating procedures). Participants were randomized to receive HCQ at 400mg once weekly vs 400mg twice weekly vs placebo for 12 weeks. The primary outcome was incidence of confirmed or probable Covid-19, assessed by self-report. Strengths and novelty of this trial design include remote procedures such as online enrolment, social media recruitment, and overnight shipping for drug dispensing. These procedures were shared with the sister trials for treatment of mild Covid-19, 7 and post-exposure prophylaxis (PEP) for Covid-19, 8 the latter was covered in Paul Sax's blog "in praise of a negative clinical trial". 9 The HCQ COVID PrEP trial planned to recruit and enroll 3,150 participants, but ultimately only 1,483 health care workers were included.

The HCQ COVID PrEP trial documented fewer primary outcome events in the HCQ arms than the placebo arm, but these results were not statistically significant. The point estimates of the hazard ratios for effect of HCQ for PrEP was 0.72 for one weekly and 0.74 for twice weekly dosing, when compared to placebo, but the 95% confidence intervals crossed the null. The authors conclude that PrEP with HCQ at doses studied did not significantly reduce confirmed or probable COVID-19 in this high-risk group. Possible reasons for the negative finding in this trial include no effect of the drug, or inadequate dosing. It is also possible that HCQ is effective at these doses, but the study was underpowered to find a difference if such a difference exists.

Due to concurrent events limiting enthusiasm for trial participation, the COVID PrEP did not fully accrue. In unpacking the possibility that the study was underpowered to see a preventive effect of HCQ if one exists, the authors acknowledge a few important limitations. These include lower than expected primary outcome events, and the inability to definitively diagnose some suspected Covid-19 events with PCR due to limited availability PCR testing in the US during the trial and the high false-negative test rate in early illness. Other study designs could have mitigated the high proportion of events lacking PCR confirmation, including patient self-collect swabs mailed back, 10 though at the time of the study design, home self-collection of swabs for SARS-CoV-2 PCR was not well validated. The failure to definitively diagnose the key primary outcome is the major weakness in the trial which affects interpretability, leaving the possibility that HCQ has an effect when given as PrEP incompletely answered.

As Rajasingham et al. discuss the failure to recruit the intended sample size, the manuscript recalls the epic journey through the trials and tribulations of HCQ during the SARS-CoV-2 pandemic. At the M a n u s c r i p t time of trial start-up, intense interest in HCQ was stoked by public figures promoting the drug despite little supporting evidence. The President of the United States (POTUS) proclaimed on twitter "HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine.", and encouraged use by stating on a televised press conference: "What do you have to lose? Take it." 11 The these statements came after a preprint was released of a small observational trial with methodological flaws. 12 Following this discourse, patients turned to internet purchasing to obtain HCQ, 13 and shortages ensued which limited access for persons with rheumatologic conditions and a bona fide use case for HCQ. 14 Despite the paucity of supporting evidence, the FDA approved Emergency Use Authorization (EUA) for HCQ. Just over a week later, Rajasingham et al. enrolled their first participant to the HCQ COVID PrEP trial on April 6 th , 2020. Enrollment was adequate for a few weeks, until further scandals ensued, including alleged political pressuring of a career government scientist at BARDA over HCQ. 15 Observational studies also began to emerge which questioned the effectiveness of off-label treatment programs to prevent disease progression or death, 16-18 and speculated on the risks for cardiac toxicity. 18, 19 When a flawed paper demonstrating harm from HCQ was published in the Lancet (later retracted), 20 the WHO Solidarity trial suspended enrollment. Rajasingham et al terminated enrollment on the HCQ COVID PrEP trial the following day on May 26 th , 2020, due to an inability to recruit participants. The FDA subsequently withdrew the EUA. 21 See timeline in the Figure. The shuttering of the HCQ COVID PrEP trial was not an isolated event, and occurred in other HCQ trials due to flagging recruitment. 22 Some trials reduced enrollment goals, including the prevention trials UW COVID-PEP, 23 and HERO-HCQ (NCT04334148), and the two large treatment trials RECOVERY 24 and WHO Solidarity 25 were terminated early due to interim analyses suggesting lack of efficacy. Despite the tumultuous ride, the data from multiple trials agree that HCQ is not effective at the moderate doses tested, for short-term or long-term use for prevention of SARS-CoV-2 as PEP 8, 23 or PrEP. 6 Likewise, conclusions converge that HCQ is not effective for treatment of Covid-19 based on retrospective observational studies 16-18 and prospective clinical trials. [24] [25] [26] Given speculation on cardiac risk via QT prolongation, 26 guidelines recommend against the use of HCQ for prevention or treatment. 27, 28 Scientific teams arrived at these conclusions by performing clinical trials during the pandemic which utilized clever designs with remote procedures to side-step the usual processes which would confer additional transmission risk, and allow for more dispersed enrollment. Rajasingham et al. should be commended on their novel and pragmatic trial approach, and for shedding light on the truth, amidst a very chaotic time in the pandemic.

Looking back, the lack of coordinated scientific responses to the pandemic in the US may have hindered the ability to arrive at definitive conclusions about HCQ used as PrEP. In contrast, the RECOVERY trial in the United Kingdom had the full backing of their National Health Service and was able to rapidly recruit trial participants nationwide to definitively determine lack of effectiveness for HCQ as treatment of COVID-19 in hospitalized participants. Premature EUA of HCQ in the US may have displaced participants from participating in proper RCTs of HCQ, as has been speculated for convalescent plasma, 29 effectively imperiling equipoise. The FDA is charged with the process to assure safety and efficacy of biomedical interventions prior to approval, and public trust is needed in the institution to assure uptake of important public health measures, like vaccines and monoclonal antibodies. M a n u s c r i p t While PPE shortages in the US have been mostly mitigated, healthcare workers remain at risk for acquiring SARS-CoV-2 and prophylactics proven to be safe and effective still do not exist. Reviewing the scientific development of HCQ as it was repurposed for SARS-CoV-2 reveals the difficulty of conducting rigorous science during a pandemic. Regulatory agencies may have competing goals to facilitate treatments for this potentially fatal condition and simultaneously study the agent. Yet the tendency to "do something" must be balanced with efforts to first determine safety and efficacy prior to widespread use. Looking forward, society is likely to derive the most benefit if the highquality science surrounding the SARS-CoV-2 vaccine efforts and monoclonal antibody development programs are left unimpeded by the drama, political meddling, and premature emergency use authorization that has surrounded the study of hydroxychloroquine. 

Coronavirus kills Chinese whistleblower doctor

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection

The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm

Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature

Internet Searches for Unproven COVID-19 Therapies in the United States

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

Official Says Doubts on Hydroxychloroquine Led to His Ouster

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Med (N Y)

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

FDA revokes authorization of drug Trump touted

Clinical trial enrollment plummets as volunteers are scared off coronavirus drugs promoted by Trump

Efficacy of Hydroxychloroquine (HCQ) for Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial. IDWeek 2020, Abstract LB-17

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

COVID-19) Treatment Guidelines. National Institutes of Health

Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19

The author would like to thank Chris Vanderwarker, MD, MBA, Emily R. Hazan, ARNP, DNP, CNM and Ruanne Barnabas, MBChB, DPhil for helpful discussions about this manuscript.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 1